Mechanistic evidence map
A side-by-side account of the perturbations, cell context and maintenance readouts actually described by the source.
CRISPR / Project brief
Proposed project · No experimental result claimedGNPTAB–STING Selectivity Dossier
A selective interaction question—not a blanket knockout program.
Hypothesis to evaluate
A bounded question before a larger commitment.
The externally reported separation between signaling and tested lysosomal functions may motivate an independently reviewed follow-up. Whether this creates a tractable, safe development opportunity remains unknown.
Replication questions
Unresolved selectivity, functional benefit, alternative explanations and context dependence that a specialist should resolve before a new study.
Modality and rights brief
A bounded discussion of possible product routes if the biology holds, with third-party rights referred for counsel review.
Capability needed
Cellular-senescence and lysosomal-biology expertise, target-validation partners and appropriate IP counsel.
Reasons to revise or stop
Stop or narrow the lead if the benefit cannot be separated from loss of essential cellular maintenance, does not independently replicate or lacks a meaningful functional endpoint.
What must be agreed before work begins
An accountable scientific lead, authorized inputs, provider responsibilities, resources, relevant approvals, data handover, interpretation criteria and a written rights position. No named institution is presented as a contracted Karam partner.
The deliverable is not a guaranteed positive finding
A well-explained negative or inconclusive result can satisfy a properly scoped project. Acceptance should be based on the agreed work and evidence, not on a favorable claim.
Source trail
Scientific summaries are adapted from the supplied 15 October 2026 CRISPR Project Assessment. Source records show the original references and review access; this release is not a new systematic review.
C01 — Yin J, Gao Y, Jing Y, et al. CRISPR screening identifies GNPTAB as a noncanonical STING activator driving cellular senescence. Protein & Cell. 27 July 2026.C06 — Madsen A, Selfjord N, Martinez-Lage M, et al. Single-cell and in vivo profiling reveal heterogeneous and organ-specific CRISPR-Cas9 off-target and translocation outcomes. Nature Communications. 26 August 2026;17:9067.Bring the capability that changes the project.
Scientific, analytical and laboratory partners can propose a specific contribution with evidence of their relevant work.